AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai ...

The U.S. Food and Drug Administration has issued an establishment inspection report with a voluntary action indicated (VAI) classification to Natco Pharma’s active pharmaceutical ingredient (API) ...

Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.

Surveying Lehigh Valley’s historical industrial sites along the Lehigh River evokes a bygone era when the region was home to ...

Shares of the company are on investors' radar after its Hyderabad plant received GMP and Quality Management certifications ...

AbbVie is investing $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its headquarters campus in North Chicago. Construction is set to begin in spring 2026, ...

CPHI & PMEC China 2026 is set to take place from 16 to 18 June 2026 at the Shanghai New International Expo Centre (SNIEC), ...

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

Indian drugmaker Aurobindo Pharma plans to scale up production of Penicillin-G to more than 10,000 metric tonnes annually within the next 12 months. The Hyderabad-based pharmaceutical company ...